AbbVie advances next-gen drug development to replace Skyrizi
What happened
AbbVie is developing a next-generation immunology drug, ABBV-466, as a potential successor to Skyrizi. Skyrizi, which generated almost $10 billion in sales in the first half of the year, faces potential biosimilar competition as its patents may expire in the U.S. by 2033. AbbVie recently announced encouraging Phase 2a results for this successor drug.
From fool.com
Why it matters
Skyrizi is currently AbbVie's single biggest growth driver. Because the drug's patents may expire by 2033, AbbVie must launch a new drug to avoid a catastrophic decline in sales once biosimilars enter the market.
AbbVie and other companies are focused on managing drug exclusivity and growing their next-generation immunology pipelines to compete for market share.
From fool.com
Who's involved
- AbbViePharmaceutical company developing the successor drug to Skyrizi
Who could feel it
Possible knock-on effectsThese are possibilities Brind reasoned out, not predictions, and not advice. Most are not stated in any report.
- AbbVieSpeculative
AbbVie might mitigate the risk of declining revenue from Skyrizi due to progress on its successor drug.
Possible ripples
Who this could reach next, traced step by step from the reporting. Possibilities worth considering, not forecasts.- Royalty Pharma could gain revenue if AbbVie's ABBV-466 succeedsRoyalty Pharma may benefit from the success of AbbVie's new immunology drugPossible
- AbbVie's new immunology drug may intensify competition with Johnson & JohnsonAbbVie's new drug may intensify competition with Johnson & JohnsonPossible
- AbbVie's new immunology drug may increase pressure on AstraZenecaAbbVie's new immunology drug may increase pressure on AstraZenecaPossible
- AbbVie's new drug may challenge Eli Lilly in immunologyAbbVie's potential successor to Skyrizi could intensify competition with Eli Lilly.Possible
Keep exploring
Part of
AbbVie and others are managing drug exclusivity, seeking next-gen immunology pipeline growth, and competing for market share.Also in this story
- The competitive landscape heats up as Sanofi's Dupixent faces challenges from AbbVie's new drug and Zumilokibart.
- AbbVie and Eli Lilly are competing in the pharmaceutical market.
The entities involved
-
AbbVie
pharmaceutical company